Key Highlights

● Net revenue fell nine per cent to C$67.6 million in fiscal Q1 2027.

● International medical revenue rose 17% to C$43.3 million.

● Canadian medical revenue fell 25% to C$20.7 million after reimbursement changes.

● Adjusted EBITDA was C$3.4 million, compared with C$10.8 million a year earlier.

Aurora Cannabis (NASDAQ:ACB), whose common shares trade on both Nasdaq and the Toronto Stock Exchange under the symbol ACB, published its first-quarter results for fiscal 2027 on 5 August 2026. The quarter ended 30 June 2026, and all figures below are in Canadian dollars. Total net revenue was $67.6 million, nine per cent lower than the $74.1 million recorded a year earlier. Medical cannabis revenue was $64.0 million, close to last year's $64.8 million, whilst consumer cannabis revenue shrank to $2.1 million from $7.9 million as the company withdrew from that channel. Selling, general and administrative costs on an adjusted basis eased slightly to $35.1 million from $36.1 million, which was not enough to offset the lower gross profit.

A tale of two medical markets

The split inside the medical business is the most revealing part of the release. Canadian medical revenue fell 25 per cent to $20.7 million, which the company attributes mainly to federal reimbursement changes that took effect on 1 April 2026 and reduced reimbursed rates by roughly 30 per cent. International medical revenue moved the other way, rising 17 per cent to $43.3 million, so overseas sales now account for about two thirds of the medical line.

Profitability weakened. Adjusted gross margin was 58 per cent, against 64 per cent previously, and adjusted EBITDA was $3.4 million compared with $10.8 million. Adjusted net income was $3.8 million, down from $6.6 million. On a statutory basis the net loss from continuing operations narrowed to $4.0 million from $10.2 million. Free cash flow was negative $5.8 million, against a positive $6.8 million a year earlier. Management had already described fiscal 2027 as a "reset year" on its June call, when it guided to lower revenue and lower adjusted EBITDA than in fiscal 2026.

Balance sheet and portfolio changes

Cash, restricted cash and short-term investments totalled $149.1 million, and the company reports no debt. Working capital was $320.0 million. That cushion matters, because it gives the business room to absorb a weaker year without needing external funding.

Portfolio pruning continues. Aurora sold its 50.1 per cent stake in the Bevo plant propagation business on 17 February 2026, and that operation is presented as discontinued. It completed the purchase of Safari Flower Company on 14 April 2026, adding a 59,000 square foot indoor facility that holds EU-GMP status; the Ontario site received its EU-GMP certificate on 23 July 2026, valid for three years. The company plans about $3.5 million of growth capital there over three years. In June, management said the acquisition price was about $26.5 million and that the Leuna facility expansion in Germany is intended to double flower output there.

Reimbursement Cuts, Germany and Poland, and a Review of US Strategy

Management reiterated its full-year fiscal 2027 outlook and expects second-quarter revenue and adjusted EBITDA to be higher than the first quarter, in sequential terms. No numeric full-year targets were given in the release, and no date for the next quarterly report was specified. The open questions are whether German and Polish growth can offset the Canadian reimbursement cut, whether margins stabilise near the guided mid-to-high 50 per cent range, and what, if anything, the company decides about its United States strategy, which it said in June was still under review.

The shift in mix is also a strategic statement. By concentrating on regulated medical markets in Germany, Poland, Australia and Canada, the company is trading consumer exposure and some near-term earnings for steadier, higher-value patient demand, although that choice leaves results more sensitive to reimbursement policy and European regulatory decisions.